Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
aminophylline hydrate · 1 trial · 1 indication
The time weighted average change from Baseline in Forced Expiratory Volume in One Second (FEV1) over the first 60 minutes after study drug administration (average change FEV1 (0-60 min)). Baseline (pre-allocation) was the last measurement obtained during the screening period.
| Arm | Type | Description |
|---|---|---|
| Montelukast 7 mg | EXPERIMENTAL | Montelukast 7 mg IV administration |
| Montelukast 14 mg | EXPERIMENTAL | Montelukast 14 mg IV administration |
| Aminophylline 250 mg | ACTIVE_COMPARATOR | Aminophylline 250 mg IV drip administration |
| Name | Type | Description |
|---|---|---|
| montelukast sodium | DRUG | Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes |
| aminophylline hydrate | DRUG | Aminophylline 250 mg IV drip infusion over 60 minutes |
Inclusion Criteria: * Adult participants with acute asthma attacks Exclusion Criteria: * Participant has any known or suspected, acute or chronic cause for their pulmonary symptoms other than asthma (e.g., COPD, chronic heart failure, etc.). * Participant has a smoking habit (15 cigarettes per da...
Aminophylline hydrate is used for asthma. It is a small molecule being studied as a treatment for asthma in adult patients. The drug is currently in Phase 3 clinical development and is being developed by Organon & Co. (NYSE: OGN).
Aminophylline hydrate is being developed by Organon & Co., a pharmaceutical company traded on the New York Stock Exchange under the ticker OGN. The drug is in Phase 3 clinical development for the treatment of asthma.
Aminophylline hydrate is in Phase 3 clinical development. It is an investigational drug being studied for the treatment of asthma. The drug has completed one Phase 3 clinical trial and is not yet approved by regulatory authorities.
Aminophylline hydrate has been studied in one completed Phase 3 clinical trial, identified as NCT00442338. This trial, titled "Study of MK-0476 in Adult Patients With Acute Asthma (0476-334)," enrolled 91 participants aged 15 years and older with asthma. The trial was active-controlled and randomized.
Aminophylline hydrate is associated with the clinical trial identifier NCT00442338, which references MK-0476 in its title. The trial studied the drug in adult patients with acute asthma, and the compound is being developed by Organon & Co. for the treatment of asthma.